BioNTech Taps Gilead's Trodelvy for Phase 3 Pumitamig TNBC Combination

summarizeSummary

BioNTech signed a clinical collaboration with Gilead to test pumitamig plus Trodelvy in first-line PD-L1 low/negative triple-negative breast cancer, and will adapt its Phase 3 ROSETTA Breast-01 trial to use the ADC instead of chemotherapy, pending regulatory approval. Gilead supplies the drug; no financial terms were disclosed.

check_boxKey Events · M&A and Partnerships · BNTX

• Gilead Collaboration on Pumitamig Combo

  BioNTech announced a clinical trial collaboration and supply agreement with Gilead Sciences to evaluate pumitamig with the TROP2-directed ADC sacituzumab govitecan (Trodelvy) as first-line treatment for locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer.

• Phase 3 ROSETTA Breast-01 Redesigned

  The global, double-blinded Phase 3 trial (NCT07173751) will replace chemotherapy with sacituzumab govitecan in the combination arm, pending regulatory authority approval, to align with the evolving standard of care.

• BioNTech Keeps Trial Sponsorship

  BioNTech continues to sponsor and lead ROSETTA Breast-01; Gilead supplies sacituzumab govitecan. No upfront, milestone or royalty terms were disclosed.

• First Pumitamig Phase 3 With an ADC

  This is the first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate; pumitamig is already in seven ongoing global Phase 3 trials and more than 10 Phase 2 novel-novel combination trials.

auto_awesomeAnalysis · BNTX · Life Sciences

BioNTech is swapping chemotherapy for Gilead's TROP2 ADC sacituzumab govitecan in the first-line arm of its Phase 3 ROSETTA Breast-01 trial, pending regulator sign-off. That matters because the trial's original comparator is being displaced as the standard of care — running against an outdated backbone risked a result that regulators and payers would discount. Gilead supplies the drug, BioNTech keeps sponsorship, so the cost is largely clinical execution rather than cash. Pumitamig is already in seven registrational-intent Phase 3 trials, and this is the first pairing with an ADC, which is the combination strategy management is betting the oncology franchise on. No financial terms were disclosed.